Stock Ratings / Health Care / NGNE / forecast

STTK (31) ACRS (31) EVO (57) CLYM (38) ⌘ Pro Terminal →

Neurogene Inc. (NGNE) 12-Month Stock Forecast & Price Target Cone

$28.82 -5.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Neurogene Inc. (NGNE) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $576.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NGNE)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NGNE Position Size: $10,000

Shares at $28.82: 347.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $20.26

$7,030

$-2,970 (-29.7%)

12M Consensus BaseTarget $25.97

$9,011

$-989 (-9.9%)

12M Bull Case BreakoutTarget $45.84

$15,906

+$5,906 (+59.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$27	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$43	69%	B
JP MorganUS Large-Cap Research	SELL	$23	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NGNE)

✓Walkthrough of NGNE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NGNE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.46%▼ DESCENDING CHANNEL

2026-10-30O $28.53H $29.38L $26.76C $28.82VOL 249.0K

RES: $39.66SUP: $18.56SMA50: $30.73SMA200: $27.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NGNE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NGNE Butterfly Map → + Track NGNE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NGNE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NGNE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NGNE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NGNE)

Health Care Rank #779 of 1016 ⚔️ STTK vs NGNE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NGNE vs. STTK, ACRS, EVO, CLYM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neurogene Inc. (NGNE) ranks #779 by composite RQD confidence (36/100, grade D-) and #427 by equity capitalization ($576.7M). Within this direct 5-issuer industry benchmark cohort, NGNE leads on earnings valuation at N/A trailing P/E, while NGNE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. EVO currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with NGNE at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NGNE ACTIVE Neurogene Inc.	D-	36/100	—	—	-35.0%	-5.26%	$576.7M	Benchmark Subject
STTK Shattuck Labs Inc.	E	31/100	—	—	-35.0%	-1.46%	$574.1M	/sttk-vs-ngne →
ACRS Aclaris Therapeutics Inc.	E	31/100	—	73.3%	-35.0%	+0.76%	$587.3M	/acrs-vs-ngne →
EVO Evotec SE	D+	57/100	—	—	—	-1.56%	$562.1M	/evo-vs-ngne →
CLYM Climb Bio Inc.	D-	38/100	—	—	-35.0%	+2.08%	$593.3M	/clym-vs-ngne →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001404644

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neurogene Inc. (NGNE) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $925.0K ) , GAAP net income of -$90.4M, operating cash flow of -$77.2M, and free cash flow of -$78.4M (-9.7% YoY). On the balance sheet, NGNE closed FY2025 with $288.6M in total assets against $0 in total debt (Altman Z-Score: 12.76, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$90.4M	-$77.2M	-$78.4M	$288.6M	—
FY2024 (FY)	2024-12-31	$925.0K	-$75.1M	-$70.6M	-$71.4M	$335.7M	—
FY2023 (FY)	2023-12-31	$0	-$36.3M	-$51.4M	-$51.4M	—	—

3. NGNE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NGNE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Neurogene Inc. (NASDAQ: NGNE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $28.82 (-5.26% 1D, market cap $576.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NGNE ranks #779 in composite RQD confidence.

How does NGNE compare to STTK and ACRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGNE carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, STTK (Shattuck Labs Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $574.1M) and ACRS (Aclaris Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $587.3M). Among the 5-stock peer group, NGNE leads on earnings multiple (N/A) while NGNE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NGNE?

Per NGNE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001404644), Neurogene Inc. generated $0 in revenue (-100.0% YoY), -$90.4M in net income, and -$78.4M in free cash flow against $288.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NGNE trading relative to its 50-day, 200-day, and 52-week technical levels?

NGNE last traded at $28.82 (-5.26% on volume of 310,014 shares), positioning the stock -6.22% below its 50-day simple moving average ($30.73) and +3.59% above its 200-day simple moving average ($27.82). Across its 52-week range of $15.93 to $43.66, NGNE sits at the 46.5% percentile with a 14-day RSI of 51.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($25.22 to $32.42).

NGNE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NGNE's 12-month stock price target?

Neurogene Inc. (NGNE) carries a 12-month consensus base price target of $25.97 (-9.9% from $28.82), with a bull-case target of $45.84 and a bear-case floor of $20.26.

Is NGNE stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NGNE D- (Sell — SELL) with an RQD Confidence score of 36/100.

Direct Sub-Reports: NGNE RQD Cockpit NGNE 12M Forecast NGNE Earnings & Move NGNE Dividends & DRIP NGNE Insiders & 13F NGNE Whale Options NGNE Profit Sankey NGNE News & Why